Lung Cancer

After years of chronic cough and misdiagnosed infections, a 2016 stage 4 ALK-positive lung cancer diagnosis led to targeted therapy that has helped since.

LiveLung announced the launch of its new Chaplain Program.

It is very important to let the world know that no matter how healthy you think you are, if you have lungs, you can potentially develop lung cancer.

The FDA has granted approval to subcutaneous Keytruda for use in adults and pediatric patients with a solid tumor.

Nancee Pronsati discusses a new patient-authored guide for managing ALK-directed treatment side effects in lung cancer and improving quality of life.

The first day of fall comes on September 22, and every year it feels like a reminder to pause.

Dr. Joshua K. Sabari sat down with Terri Conneran at the 2025 World Conference on Lung Cancer for a conversation on the importance of biomarker testing.

Dr. Geoffrey Liu discussed findings from the phase 2 TRUST-II clinical trial evaluating Ibtrozi (taletrectinib) among patients with ROS1-positive non-small cell lung cancer.

Early trial results report progression-free survival and response rates for ateganosine, spevatamig, Annamycin and pumitamig; studies are currently enrolling.

Dr. Joshua Sabari spoke with advocate Chris Conneran on his journey from caregiver to champion for KRAS-mutant cancer patients and families.

Lutathera demonstrated antitumor activity in patients with metastatic bronchopulmonary neuroendocrine tumors.

For patients with MET exon 14-altered NSCLC, Tepmetko was associated with frequent side effects, although the safety profile is considered manageable.

Receiving a “Stand Up to Cancer Day” email gave me the strength to support a friend through her darkest cancer days.

Dr. Josh Sabari and Max Doppelt explore challenges in trial enrollment and the potential of emerging therapies to offer hope for patients diagnosed today.

When I think about standing up to cancer, I cannot separate the words from my own story.

For patients with advanced non-small cell lung cancer who progressed on two or more prior regimens, THIO with Libtayo elicited positive responses.

Dr. Thomas Jankowski explained that THIO, a telomerase inhibitor, is being studied with Libtayo to help overcome resistance in advanced lung cancer.

Advances are reshaping treatment for small cell lung cancer, with immunotherapy and emerging options offering hope for longer survival and potential cures.

Perioperative immunotherapy for the treatment of non-small cell lung cancer is starting to exhibit survival benefits among patients, research has shown.

Over the past 20 years, there have been dramatic advances in treatment options for people diagnosed with non-small cell lung cancer

LiveLung invites the Pittsburgh community to its monthly educational meeting.

CURE spoke with Dr. Xiuning Le during the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer.

Patients with advanced, pretreated ROS1-positive NSCLC treated with zidesamtinib saw an objective response rate of 44%.

For some with previously untreated locally advanced or metastatic non-small cell lung cancer Rybrevant plus Lazcluze improved overall survival.

CURE spoke with Dr. Alexander Spira to learn what patients need to know about the KRAS G12C mutation and its treatment strategies.